Daishin Securities targets KOSDAQ technology-special listing in H1 2026
[by Ji, Yong Jun] Ubix 해외 바카라사이트, a company specializing in the development of targeted protein degradation (TPD) 해외 바카라사이트, has successfully passed the technology evaluation required for a technology-special listing on the KOSDAQ.
Ubix Therapeutics announced on August 21 that it has obtained ‘A’ ratings from both ECREDIBLE and Korea Rating & Data (KoDATA), the professional rating agencies designated by the Korea Exchange. The company intends to file for a preliminary listing review on the KOSDAQ in the second half of this year, with the goal of completing its listing in the first half of 2026. Daishin Securities will serve as the lead underwriter.
Ubix Therapeutics was founded in June 2018 by CEO BK Seo. It is developing a new TPD anticancer drug using its platform technology, ‘Degraducer.’ It has raised a total of KRW 67.4 billion (approximately USD 48.2 million) in accumulated investment.
Ubix Therapeutics is currently conducting a Phase 1 clinical trial of its lead pipeline, ‘UBX-303-1’ (development code), in the United States and Korea for patients with relapsed or refractory B-cell lymphoma. In July 2024, the company successfully out-licensed its prostate cancer treatment candidate, UBX-103, to Yuhan Corporation. More recently, in February of this year, the company entered into a joint research agreement with Y-Biologics to develop a novel degrader-antibody conjugate (DAC) therapy.
"We are honored to be recognized for our technological strength and consistent commercialization efforts. Moving forward, we remain committed to successfully completing our KOSDAQ listing and growing into a global biotechnology company," said BK Seo, CEO of Ubix Therapeutics.